153 related articles for article (PubMed ID: 32786957)
1. Factors Influencing the Immunogenicity and Immunotoxicity of Cyclic RGD Peptide-Modified Nanodrug Delivery Systems.
Wang X; Meng N; Wang S; Lu L; Wang H; Zhan C; Burgess DJ; Lu W
Mol Pharm; 2020 Sep; 17(9):3281-3290. PubMed ID: 32786957
[TBL] [Abstract][Full Text] [Related]
2. Liposomes with cyclic RGD peptide motif triggers acute immune response in mice.
Wang X; Wang H; Jiang K; Zhang Y; Zhan C; Ying M; Zhang M; Lu L; Wang R; Wang S; Burgess DJ; Wang H; Lu W
J Control Release; 2019 Jan; 293():201-214. PubMed ID: 30527753
[TBL] [Abstract][Full Text] [Related]
3. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
4. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors.
Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X
Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250
[TBL] [Abstract][Full Text] [Related]
5. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
Li C; Shen J; Wei X; Xie C; Lu W
J Drug Target; 2012 Apr; 20(3):264-71. PubMed ID: 22233211
[TBL] [Abstract][Full Text] [Related]
7. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
9. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
10. RGD-modified lipid disks as drug carriers for tumor targeted drug delivery.
Gao J; Xie C; Zhang M; Wei X; Yan Z; Ren Y; Ying M; Lu W
Nanoscale; 2016 Apr; 8(13):7209-16. PubMed ID: 26972577
[TBL] [Abstract][Full Text] [Related]
11. ɑ
Li J; Chai Z; Lu J; Xie C; Ran D; Wang S; Zhou J; Lu W
J Control Release; 2020 Jun; 322():542-554. PubMed ID: 32277962
[TBL] [Abstract][Full Text] [Related]
12. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization.
Wang HW; Jiang PL; Lin SF; Lin HJ; Ou KL; Deng WP; Lee LW; Huang YY; Liang PH; Liu DZ
Acta Biomater; 2013 Mar; 9(3):5681-8. PubMed ID: 23159567
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) Peptide.
Chen Y; Zhang W; Huang Y; Gao F; Fang X
PLoS One; 2016; 11(3):e0149952. PubMed ID: 26930626
[TBL] [Abstract][Full Text] [Related]
14. Liposomes modified with cyclic RGD peptide for tumor targeting.
Dubey PK; Mishra V; Jain S; Mahor S; Vyas SP
J Drug Target; 2004 Jun; 12(5):257-64. PubMed ID: 15512776
[TBL] [Abstract][Full Text] [Related]
15. Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.
Chen C; Duan Z; Yuan Y; Li R; Pang L; Liang J; Xu X; Wang J
ACS Appl Mater Interfaces; 2017 Feb; 9(7):5864-5873. PubMed ID: 28128553
[TBL] [Abstract][Full Text] [Related]
16. Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes.
Wang X; Meng N; Wang S; Zhang Y; Lu L; Wang R; Ruan H; Jiang K; Wang H; Ran D; Zhan C; Yu K; Burgess DJ; Lu W
J Control Release; 2019 Dec; 316():381-392. PubMed ID: 31730912
[TBL] [Abstract][Full Text] [Related]
17. [In vivo imaging in tumor-bearing animals and pharmacokinetics of PEGylated liposomes modified with RGD cyclopeptide].
Tu LX; Xu YH; Tang CY; Deng LH; Wu CB
Yao Xue Xue Bao; 2012 May; 47(5):646-51. PubMed ID: 22812011
[TBL] [Abstract][Full Text] [Related]
18. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer.
Zhao H; Wang JC; Sun QS; Luo CL; Zhang Q
J Drug Target; 2009 Jan; 17(1):10-8. PubMed ID: 19016068
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.
Judge A; McClintock K; Phelps JR; Maclachlan I
Mol Ther; 2006 Feb; 13(2):328-37. PubMed ID: 16275098
[TBL] [Abstract][Full Text] [Related]
20. Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma cancer cells.
Khabazian E; Vakhshiteh F; Norouzi P; Fatahi Y; Dinarvand R; Atyabi F
J Drug Target; 2022 Jun; 30(5):522-533. PubMed ID: 34482780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
